NRIX vs XPRO Comparison

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.